1. Home
  2. CPSS vs ACRS Comparison

CPSS vs ACRS Comparison

Compare CPSS & ACRS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • CPSS
  • ACRS
  • Stock Information
  • Founded
  • CPSS 1991
  • ACRS 2012
  • Country
  • CPSS United States
  • ACRS United States
  • Employees
  • CPSS N/A
  • ACRS N/A
  • Industry
  • CPSS Finance: Consumer Services
  • ACRS Biotechnology: Pharmaceutical Preparations
  • Sector
  • CPSS Finance
  • ACRS Health Care
  • Exchange
  • CPSS Nasdaq
  • ACRS Nasdaq
  • Market Cap
  • CPSS 193.8M
  • ACRS 165.7M
  • IPO Year
  • CPSS 1992
  • ACRS 2015
  • Fundamental
  • Price
  • CPSS $9.77
  • ACRS $1.59
  • Analyst Decision
  • CPSS
  • ACRS Strong Buy
  • Analyst Count
  • CPSS 0
  • ACRS 9
  • Target Price
  • CPSS N/A
  • ACRS $9.25
  • AVG Volume (30 Days)
  • CPSS 23.8K
  • ACRS 1.3M
  • Earning Date
  • CPSS 07-29-2025
  • ACRS 08-06-2025
  • Dividend Yield
  • CPSS N/A
  • ACRS N/A
  • EPS Growth
  • CPSS N/A
  • ACRS N/A
  • EPS
  • CPSS 0.79
  • ACRS N/A
  • Revenue
  • CPSS $188,776,000.00
  • ACRS $17,777,000.00
  • Revenue This Year
  • CPSS $146.82
  • ACRS N/A
  • Revenue Next Year
  • CPSS $18.24
  • ACRS $11.77
  • P/E Ratio
  • CPSS $12.58
  • ACRS N/A
  • Revenue Growth
  • CPSS N/A
  • ACRS N/A
  • 52 Week Low
  • CPSS $7.99
  • ACRS $1.05
  • 52 Week High
  • CPSS $12.73
  • ACRS $5.17
  • Technical
  • Relative Strength Index (RSI)
  • CPSS 58.96
  • ACRS 59.88
  • Support Level
  • CPSS $9.79
  • ACRS $1.44
  • Resistance Level
  • CPSS $10.18
  • ACRS $1.52
  • Average True Range (ATR)
  • CPSS 0.29
  • ACRS 0.10
  • MACD
  • CPSS -0.02
  • ACRS 0.00
  • Stochastic Oscillator
  • CPSS 74.14
  • ACRS 79.17

About CPSS Consumer Portfolio Services Inc.

Consumer Portfolio Services Inc is a U.S based company operating in the specialty finance sector. Its business is to purchase and service retail automobile contracts originated by franchised automobile dealers and, to a lesser extent by select independent dealers in the United States in the sale of new and used automobiles, light trucks, and passenger vans. Through its automobile contract purchases, the company provides indirect financing to the customers of dealers having limited credit histories, low incomes, or past credit problems, who it refers to as sub-prime customers. It serves as an alternative source of financing for dealers, facilitating sales to customers.

About ACRS Aclaris Therapeutics Inc.

Aclaris Therapeutics Inc is a clinical-stage biopharmaceutical company that operates in the United States. It focuses on developing novel drug candidates for immuno-inflammatory diseases. The company operates in two reportable segments: therapeutics and contract research. The therapeutics segment is focused on identifying and developing inventive therapies to address unmet needs for immuno-inflammatory diseases, and the contract research segment is engaged in providing laboratory services. A majority of the company's revenue is derived from the therapeutics segment. The various drug candidates in its product pipeline are Zunsemetinib, which is an Oral MK2 Inhibitor; ATI-2138, an ITJ Inhibitor; Bosakitug, ATI-052, and Lepzacitinib.

Share on Social Networks: